News

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

An intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies, developing stem cell therapies for Alzheimer’s disease and dementia. The first results of the…

Alzheimer’s Researchers Discover Bryostatin Can Slow, Reverse Disease Progression

Researchers from the Blanchette Rockefeller Neuroscience Institute (BRNI) have gathered evidence of the possible role of protein kinase C epsilon (PKCe) in the treatment of Alzheimer’s disease (AD). The news was recently announced by Neurotrope, a pharmaceutical company collaborating with BRNI in the development of bryostatin, a potent modulator of PKCe,…

National Plans Announced to Study FTD Along with Alzheimer’s Disease

Individuals with frontotemporal degeneration (FTD) may soon benefit from research priorities directed toward curing Alzheimer’s disease and other forms of dementia. The Association of Frontotemporal Degeneration (AFTD) broke word of plans to formally include FTD in national research priorities by the year 2025. According to AFTD Executive Director Susan…

Chance Discovery Of Normal Cognition In Patient Without Apolipoprotein E Could Point To New Alzheimer Treatments

A new free access paper published online before print in the journal JAMA Neurology, entitled, “Effects of the Absence of Apolipoprotein E on Lipoproteins, Neurocognitive Function, and Retinal Function” (JAMA Neurol. Published online August 11, 2014. DOI: 10.1001/.jamaneurol.2014.2011) documents a 40-year-old African American man referred…